<DOC>
	<DOC>NCT00171379</DOC>
	<brief_summary>The aim of the study is to evaluate the safety and efficacy of equimolar conversion from MMF to enteric-coated mycophenolate sodium, in renal transplant patients receiving cyclosporine.</brief_summary>
	<brief_title>Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>First or second (single or double) deceased or living donor kidney transplant received at least six months previously; Immunosuppressive therapy with cyclosporin and mycophenolate mofetil (MMF); Receiving an MMF dose of &lt;2/g/day because of any adverse event and/or altered laboratory test result attributed to MMF â€¢ Subjects expected to discontinue cyclosporin therapy; Patients with thrombocytopenia (&lt;75,000/mm3), an absolute neutrophil count of &lt;1,500/mm3 and/or leukopenia (&lt;2,500/mm3), or anemia (hemoglobin &lt;6 g/dl) at baseline; Patients experiencing an acute rejection in the previous two months, with inadequate (creatininemia &gt;2.5 mg/dL) or worsening renal function in the previous two months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Kidney transplantation; acute rejection; gastrointestinal adverse events; quality of life; mycophenolate sodium.</keyword>
</DOC>